Emerging Pharma Leadership Awards - Scott Cormack

Oct 15, 2009
By Pharmaceutical Executive
Emerging Pharma Leadership Awards - Scott Cormack
Scott Cormack,
President and CEO,
OncoGenex Pharmaceuticals

“OncoGenex’s product pipeline is comprised of a majority of product candidates designed to inhibit novel targets. The company’s randomized Phase II data in prostate cancer, which showed a 40 percent reduction in the rate of death compared to the gold standard therapy, demonstrates the success of this approach.” Listen to the Podcast for more coverage".


Add this Podcast feed to your media player